Ad
related to: luspatercept fda approval thalassemia disease guidelines- Sign Up
Stay up to date. Sign up to receive
the latest thalassemia information.
- Management
Find the latest thalassemia
management guidelines.
- Resources
Explore resources for HCPs.
See study results & more.
- For Patients
Visit this website if you are a
patient seeking information.
- Sign Up
Search results
Results from the WOW.Com Content Network
Luspatercept, sold under the brand name Reblozyl, is a medication used for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. [ 5 ] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication .
Luspatercept is a drug used to treat anemia in adults with β-thalassemia, it can improve the maturation of red blood cells and reduce the need for frequent blood transfusions. It is administered by injection every three weeks. Luspatercept was authorised for use in the US in 2019 and by the European Medicines Agency in 2020. [78]
Counseling is indicated in all persons with genetic disorders, especially when the family is at risk of a severe form of disease that may be prevented. [4] Severe thalassemia : Patients with severe thalassemia require medical treatment. A blood transfusion regimen was the first measure effective in prolonging life. [2]
For premium support please call: 800-290-4726 more ways to reach us
The US Food and Drug Administration has approved a second use for the first CRISPR-based medicine, Casgevy, which was approved in December to treat sickle cell disease.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
The Food and Drug Administration has approved lecanemab, a drug developed by Eisai and Biogen with the goal of slowing the progression of Alzheimer’s disease. FDA grants full approval to new ...
In combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant ...
Ad
related to: luspatercept fda approval thalassemia disease guidelines